AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00456521 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive group lifestyle modification counseling
Study NCT04276597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: 177Lu labeled somatostatin receptors targeting ligand
Study NCT02095587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 25 mg single oral capsule
Study NCT01773382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight reduction
Description: 1. Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)~2. Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.~3. Daily body weight measurement.~4. Record food diary
Study NCT03140384 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Assess the efficacy and side effects of Misoprostol according to the route of administration
Description: Assess the efficacy and side effects of Misoprostol according to the route of administration
Study NCT06119360 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Face-to-face approach
Description: A front-facing approach and insert the lightwand following the patient's tongue base curvature without scooping movement
Study NCT06119360 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional approach
Description: Patients were positioned supine and the intubator stood above the patient's head. Opening the mouth and slightly pulling the mandible with one hand, the intubator inserted the lightwand-tracheal tube assembly at midline into the patient's mouth under the ambient light being turned off. To identify the location of the lighted tip, the intubator could move the lightwand back and forth gently, Once the red light of the tip was located at the midline of the patient's neck, the pre-launched tube was inserted smoothly into the patient's airway unless there was no resistance
Study NCT01260285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: 10 mg PO once
Study NCT05004753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemisinin
Description: a herbal supplement
Study NCT05004753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: corticosteroids
Study NCT06182189 — intervention group
Intervention type: OTHER
Intervention: Observation of patients with a benign prostatic hyperplasia condition
Description: Observation of patients with a benign prostatic hyperplasia condition who have undergone surgery
Study NCT01810354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Study NCT01810354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Study NCT01113801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2382770
Description: Subcutaneous injection given monthly for 12 months
Study NCT01113801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection given monthly for 12 months
Study NCT03080311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
Study NCT01354951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prostate Biopsy, Focal Brachytherapy , Assessment of QOL
Description: A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
Study NCT01949051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocabastine
Description: Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
Study NCT01949051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
Study NCT01550640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
Study NCT00492661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus With Diet and Exercise Intervention
Description: Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
Study NCT03595033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad app-based intervention
Description: The 1-hour of home based intervention will break into three 20-min sessions, each including iPad apps targeting one of the three domains of deficits: visual attention, visual-spatial reasoning, and visual-motor skills.
Study NCT00109889 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: magnetic resonance imaging
Description: magnetic resonance imaging (MRI)
Study NCT00109889 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: positron emission tomography
Description: positron emission tomography (PET)
Study NCT02736409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Budesonide Suspension (OBS)
Description: OBS 2mg twice daily
Study NCT02736409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo dose
Study NCT00774319 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional radiotherapy with 'high' dose cisplatin
Description: radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.~100 mg/m2 cisplatin iv on day 1, 22 and 43
Study NCT00774319 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: accelerated radiotherapy with 'low' dose cisplatin
Description: Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
Study NCT00449540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Magnetic Stimulation (TMS) Device
Description: Transcranial Magnetic Stimulation Device treatment
Study NCT00449540 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS Device
Description: Simulated Sham treatment without TMS delivery
Study NCT03055351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop&Go Intervention
Description: Stop\&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
Study NCT04539847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-end hearing aid
Description: hearing aid with premium level of technology
Study NCT04539847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basic hearing aid
Description: hearing aid with basic level of technology
Study NCT01366560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active
Description: GSK962040 125mg
Study NCT01366560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT04542655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ergometer Cycling followed by treadmill running
Description: The participants undergo ergometer cycling, treadmill running and rest.
Study NCT04542655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treadmill Running followed by ergometer cycling
Description: The participants undergo treadmill running, ergometer cycling and rest.
Study NCT04542655 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rest
Description: The participants undergo ergometer cycling, treadmill running and rest.
Study NCT00759954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate sustained-release capsules
Description: 1 x 200 mg, single-dose capsule
Study NCT03606551 — intervention group
Intervention type: DEVICE
Intervention: EXD-959 Bracket System
Description: EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.
Study NCT00759954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate sustained-release) capsules
Description: 2 x 100 mg, single-dose capsule
Study NCT02368431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
Study NCT02368431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00526994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screened
Description: Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
Study NCT04182321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo & Entecavir
Description: Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
Study NCT01698450 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive intervention with focused ultrasound (ExAblate 4000)
Description: Non-invasive brain intervention using MR-guided focused ultrasound
Study NCT03384563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms
Study NCT03384563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 9 arms
Study NCT00387179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5mg, pill, once
Study NCT00387179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylxanthine
Description: 2.9 mg/kg, pill, once
Study NCT00387179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: Bright light exposure
Study NCT01551290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
Study NCT01551290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
Study NCT02141490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: 7.5mg/kg intravenous (IV) infusion
Study NCT02141490 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: 3 MRIs: pre-infusion, 24 and 48 hours post-infusion
Study NCT01550341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine/naloxone
Description: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
Study NCT01550341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
Study NCT01213186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose of MSC
Description: Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5\*10E6/kg for 48 weeks.
Study NCT01213186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose of MSC treatment
Description: Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5\*10E6/kg for 48 weeks.
Study NCT02451683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiology Assessment of Time Domain
Description: Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
Study NCT02451683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiology Assessment of Location
Description: Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
Study NCT02451683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training with some stimulation
Description: motor task combined with real or sham stimulation
Study NCT02451683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training with some stimulation
Description: motor task combined with real or sham stimulation
Study NCT02451683 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training with some stimulation
Description: motor task combined with real or sham stimulation
Study NCT04038892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Chest Physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
Study NCT04038892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy
Description: Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
Study NCT04038892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Based Exercise Training
Description: Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
Study NCT04038892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BreathingLabs Breathing Games Based Exercise Training
Description: BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
Study NCT04531358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal spray
Description: application of nasal spray
Study NCT04531358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no treatment
Description: no treatment
Study NCT01884558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isavuconazole
Description: oral
Study NCT01884558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral
Study NCT00011414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tariquidar
Description: IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
Study NCT01241344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brincidofovir
Description: * Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~* Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg).
Study NCT01241344 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~• Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg).
Study NCT03807297 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Injection dexmedetomidine
Description: alpha 2 a agonist used for sedation, analgesia
Study NCT03807297 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Injection, Propofol, 10 Mg
Description: non barbiturate type of intravenous anaesthetic drug
Study NCT03807297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sevoflurane
Description: inhalational anaesthetic agent
Study NCT03807297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: nitrous oxide
Description: inhalational anaesthetic agent
Study NCT01960127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise
Study NCT01960127 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Intervention
Description: No Intervention
Study NCT02952482 — intervention group
Intervention type: PROCEDURE
Intervention: newborns testing for ALD
Description: Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
Study NCT03426475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interprof ACT measures
Description: Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
Study NCT02076399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium
Description: Fostamatinib (100 mg PO bid or 150 mg PO bid)
Study NCT02076399 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo tablet PO bid (morning and evening) over the course of 24 weeks
Study NCT01140568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: 400mg po (orally) BID (twice daily)
Study NCT03348956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EPR Oximetry
Description: Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
Study NCT03852355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: ), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level
Study NCT03852355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: received systemic steroids oral prednisolone tablet, 10 mg/day
Study NCT00596570 — intervention group
Intervention type: PROCEDURE
Intervention: PCI
Description: Percutaneous coronary interventiom
Study NCT02097810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Study NCT02685020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV
Description: Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5\*10\^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
Study NCT02685020 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140
Description: The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
Study NCT02685020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, 0.5 mL injection administered intramuscularly.
Study NCT02186912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nobel Active, Nobel Procera IBO